Precision BioSciences' PBGENE-HBV shows durable HBsAg reduction in Phase 1; cash runway to H2 2027

PRECISION BIOSCIENCES INC

Cohort 1 (0.2 mg/kg): well-tolerated; best HBsAg reductions of 56%, 69%, and 47% across three patients.
Patient 1 maintained ~50% HBsAg reduction 7 months after initial dose, indicating durable antiviral editing.
Cohort 2 (0.4 mg/kg) shows no Grade 3+ AEs; DMC approved escalation to Cohort 3.
Cash runway extended to H2 2027 via ~$25M annual operating expense reduction program starting July 2025.
Dr. Mark Sulkowski appointed Head Clinical Development Advisor for PBGENE-HBV and later-stage trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.